B
Bull
Bull · 25%ELVN
$25.90
Scenario price
$37.320
-1.907 (-5.11%)At close
Loading chart…
- High
- 39.465
- Open
- 39.330
- VWAP
- 37.91
- Volume
- 1.19M
- Mkt Cap
- 1.10B
- Low
- 36.955
- Amount
- 45.06M
- EV/EBITDA, TTM
- 0.00
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI). The Company's second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations.
AI analysis of Enliven Therapeutics Inc (ELVN)
BuyEnliven Therapeutics Inc is a good buy right now due to its strong cash reserves of $895.2 million, which ensures liquidity into 2030, and a current price of $37.32 significantly below analyst price targets ranging from $70 to $82. The main risk is the negative earnings trend, with an EPS of -0.49 reported last quarter, missing expectations by $0.10.
Valuation Metrics
The current forward P/E ratio for Enliven Therapeutics Inc (ELVN) is 0.00, compared to its 5-year average forward P/E of -9.29.
Alphio AI Price Scenarios for ELVN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding ELVN
Events Timeline
News
5.010-14PRnewswireEnliven Appoints New Board Member Ahead of Phase 3 Trial
9.010-06NewsfilterEnliven on Track to Initiate ENABLE-2 Trial by Year-End 2026
6.010-02CNBCLatest Ratings and Outlook from Wall Street
6.010-01CNBCLatest Wall Street Rating Updates
1.009-03PRnewswireEnliven Therapeutics Announces Upcoming Investor Conference Participation
ELVN FAQ — answered by Alphio AI
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI). The Company's second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Enliven Therapeutics Inc is a good buy right now due to its strong cash reserves of $895.2 million, which ensures liquidity into 2030, and a current price of $37.32 significantly below analyst price targets ranging from $70 to $82. The main risk is the negative earnings trend, with an EPS of -0.49 reported last quarter, missing expectations by $0.10.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.